2. Academic Validation
  3. Novel protein kinase inhibitor TT-00420 inhibits gallbladder cancer by inhibiting JNK/JUN-mediated signaling pathway

Novel protein kinase inhibitor TT-00420 inhibits gallbladder cancer by inhibiting JNK/JUN-mediated signaling pathway

  • Cell Oncol (Dordr). 2022 Aug;45(4):689-708. doi: 10.1007/s13402-022-00692-7.
Huijie Miao # 1,  Yajun Geng # 1,  Yang Li # 1,  Shijie Tang # 2 3,  Feiling Feng # 4,  Weijian Li 1,  Yongsheng Li 1,  Liguo Liu 1,  Rui Zhang 5,  Shimei Qiu 6 7,  Ying Wu 6 7,  Zeyu Wang 1,  Ziyi Wang 1,  Ziyu Shao 8,  Ke Liu 1,  Lu Zou 1,  Mao Yang 1,  Yuhao Zhao 1,  Chen Chen 6 7,  Zhizhen Li 4,  Dadong Zhang 9,  Peng Peng 10,  Xiaoyan Qiang 10,  Frank Wu 10,  Yongning He 6,  Luonan Chen 2 11 12,  Dongxi Xiang 13,  Xiaoqing Jiang 14,  Maolan Li 15 16,  Yun Liu 17,  Yingbin Liu 18 19 20
Affiliations

Affiliations

  • 1 Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.
  • 2 State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, CAS Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai, 200031, China.
  • 3 University of Chinese Academy of Sciences, Beijing, 100049, China.
  • 4 Department of Biliary Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, 200433, China.
  • 5 Department of Hepatobiliary Surgery, the First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, 710061, China.
  • 6 State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai, 200127, China.
  • 7 Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, 200127, China.
  • 8 Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
  • 9 3D Medicines Lnc, Shanghai, 201114, China.
  • 10 Transthera Sciences (Nanjing), lnc, Nanjing, 210032, Jiangsu, China.
  • 11 Center for Excellence in Animal Evolution and Genetics, Chinese Academy of Sciences, Kunming, 650223, China.
  • 12 Key Laboratory of Systems Health Science of Zhejiang Province, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Hangzhou, 310024, China.
  • 13 State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai, 200127, China. dxiang@shsmu.edu.cn.
  • 14 Department of Biliary Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, 200433, China. jxqehbh@sina.com.
  • 15 Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China. limaolan6@163.com.
  • 16 Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, 200127, China. limaolan6@163.com.
  • 17 State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai, 200127, China. superliuyun@fudan.edu.cn.
  • 18 Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China. laoniulyb@shsmu.edu.cn.
  • 19 State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai, 200127, China. laoniulyb@shsmu.edu.cn.
  • 20 Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, 200127, China. laoniulyb@shsmu.edu.cn.
  • # Contributed equally.
PMID: 35870050 DOI: 10.1007/s13402-022-00692-7
Abstract

Purpose: This study aimed to investigate the efficiency of our chemically synthesized TT-00420, a novel spectrum-selective multiple protein kinase inhibitor, in cultured cells and animal models of gallbladder Cancer (GBC) and explore its potential mechanism.

Methods: Multiple GBC models were established to assess the anti-tumor efficiency, toxicity, and pharmacokinetics of TT-00420. Integrated transcriptomic, proteomic and phosphoproteomic analysis was conducted to identify potential downstream effectors of TT-00420. Western blotting, qRT-PCR, nuclear-cytoplasm separation, and immunofluorescence were performed to confirm the multi-omic results and explore the molecular mechanism of TT-00420. Immunohistochemistry was used to detect FGFR1 and p-FGFR1 expression levels in GBC samples. Autodock software was utilized to investigate the potential binding mode between the TT-00420 and the human FGFR1.

Results: We found that TT-00420 exerted potent growth inhibition of GBC cell lines and multiple xenograft models. Treatment of mice with 15 mg/kg TT-00420 via gavage displayed a half-life of 1.8 h in the blood and rapid distribution to the liver, kidneys, lungs, spleen, and tumors at 0.25 h, but no toxicity to these organs over 2 weeks. Multi-omic analysis revealed c-Jun as a potential downstream effector after TT-00420 treatment. Mechanistically, TT-00420 showed rigorous ability to block FGFR1 and its downstream JNK-JUN (S63/S73) signaling pathway, and induce c-Jun S243-dependent MEK/ERK reactivation, leading to FASLG-dependent tumor cell death. Finally, we found that FGFR1 and p-FGFR1 expression was elevated in GBC patients and these levels correlated with decreased patient survival.

Conclusions: TT-00420 shows potent antitumor efficacy and may serve as a novel agent to improve GBC prognosis.

Keywords

Cell Apoptosis; Gallbladder cancer; Multiple kinase inhibitor; Phosphoproteomics; Proteomics.

Figures
Products